Georgetown University Medical Center Apr 18 2025 Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national coverage determination that established coverage standards for NGS testing. The analysis by Georgetown University researchers and colleagues, and funded by a grant from the National Cancer Institute at the National Institutes of Health, appears